Asymchem Q3 2026: Net Profit Jumps 81.5% as Domestic Revenue Grows 42.8% and New Modalities Reach 35.6% of Sales

Revenue for the first nine months reached RMB 5.395B (+16.52% YoY), with net profit of RMB 852M (+6.49%). Q3 alone delivered RMB 1.788B in revenue (+24.04%) and RMB 332M in net profit (+81.49%). Small-molecule CDMO grew only 3.59%, while emerging businesses rose 50.20% to RMB 1.923B and domestic client revenue climbed 42.83%. Management guides full-year revenue growth of 19%-22%, implying a sharply back-loaded Q4.

On the evening of 22 October, Asymchem (002821.SZ) released its 2026 third-quarter report. Nine-month revenue reached RMB 5.395B, up 16.52% YoY (20.00% at constant currency); net profit attributable to shareholders was RMB 852M, up 6.49%; non-GAAP net profit was RMB 728M, essentially flat (+0.04%); adjusted net profit reached RMB 1.074B, up 21.81%.

The quarterly breakdown reveals a clearer inflection than the cumulative numbers. Q3 revenue was RMB 1.788B, up 24.04% YoY (28.25% at constant currency), a marked acceleration from the 16.52% nine-month pace. Q3 net profit was RMB 332M, up 81.49%, and Q3 non-GAAP net profit was RMB 203M, up 25.70%. The gap between nine-month net profit growth of 6.49% and Q3 growth of 81.49% tells the story: the first-half profit base was compressed, and the release of concentrated second-half deliveries restored leverage quickly.

Small molecules at 3.59% versus emerging business at 50.20%

The segment split is the most informative part of the report. Small-molecule CDMO revenue was RMB 3.465B in the first nine months, up 3.59% YoY (7.44% at constant currency) - still single-digit growth for the core franchise, well below the double-digit expansion seen before 2024. But the gross margin held at 47.97% (+0.97 ppts YoY; 49.83% and +2.84 ppts at constant currency), confirming that process premiums on high-complexity projects remain intact and that pricing pressure has not broken profitability.

Emerging businesses (chemical macromolecules, biologics and formulations) generated RMB 1.923B, up 50.20% YoY and 52.69% at constant currency, lifting their share of total revenue to 35.6%. The company attributes the growth to chemical macromolecules breaking through in three frontier areas: peptides, oligonucleotides and ADC toxin-linkers, with pipelines spanning early clinical through commercial stages. Note, however, that the emerging-business gross margin is 30.95% (+0.41 ppts), well below the 47.97% of small molecules. A mix shift toward emerging businesses mechanically produces a phase of rising growth with structurally lower gross margin - the key premise for understanding Asymchem's margin trajectory over the next two years.

Client mix: big pharma +22.4%, domestic +42.8%

By client type, revenue from large pharmaceutical companies reached RMB 2.513B (+22.40%), while revenue from small and mid-sized pharma reached RMB 2.882B (+11.84%). By geography, overseas client revenue was RMB 3.623B (+11.64% at constant currency) and domestic client revenue was RMB 1.772B (+42.83%) - domestic growth running at nearly four times the overseas rate, with its share of revenue rising to 32.9%.

The domestic surge has a clear upstream driver: capital returning to Chinese biotech through out-licensing. According to PharmaCube, as of 17 October China had recorded 209 out-licensing deals in 2026 with more than USD 8B in upfront payments and over USD 140B in total deal value, all exceeding full-year 2025 levels. The first thing a biotech does with an upfront payment is push pipelines into late-stage clinical development and process scale-up - precisely the source of domestic CDMO orders. Asymchem's +42.83% domestic growth and the Chinese assets licensed to US and European biotechs are two ends of the same cash flow.

Full-year guidance of 19%-22% requires a heavily back-loaded Q4

The company stated that new orders grew at a double-digit rate during the period, that late-stage and commercial CDMO projects carry large volumes and long, highly planned execution cycles with deliveries typically concentrated in the second half, and that based on the undelivered order book, Q4 deliveries will be substantially larger than in the current quarter. Management guides full-year 2026 revenue growth of 19%-22%.

That is a tight arithmetic constraint. On nine-month revenue of RMB 5.395B, 19%-22% full-year growth implies revenue of roughly RMB 7.44-7.63B (against about RMB 6.25B in 2025), which means Q4 alone must deliver RMB 2.05-2.24B - up 15%-25% sequentially and equivalent to booking 28%-30% of the year in the final quarter. Execution depends on three things: whether commercial projects are scheduled as planned, whether new capacity (peptide and oligonucleotide synthesis lines, high-potency suites) comes online on time, and whether year-end FX continues to distort RMB-reported revenue.

One accounting caveat worth flagging: nine-month operating cash flow was RMB 605M, down 47.10% YoY, with a weighted average ROE of 4.75%. Revenue and profit are accelerating but cash flow is not - typically a sign of inventory and receivables build-up ahead of the Q4 delivery peak. If Q4 converts on schedule, cash flow recovers in the annual report; if deliveries slip, it becomes working-capital pressure.

The sector context: a diverging Q3 season

This week's domestic CXO results show clear divergence. WuXi AppTec raised full-year revenue guidance from RMB 51.3-53.0B to RMB 58.5-60.5B during the first three quarters, with TIDES growth guided at roughly 45% for the year (UBS estimate). Pharmaron's new orders grew more than 50% YoY. Asymchem posted double-digit new order growth, a 54% rise in backlog, and the steepest Q3 profit leverage among the three. What they share is improving leading indicators on orders; what differs is the slope of the small-molecule recovery - WuXi's small-molecule D&M pipeline keeps migrating toward late-stage and commercial work, while Asymchem's small-molecule base remains in a plateau of single-digit growth paired with high margins.

The same week, Samsung Biologics saw its Q3 operating margin fall from 50.4% to 42.9% (Plant 5 ramp, Rockville consolidation, FX) - trading margin for share. Lonza, at its October Capital Markets Day, raised its mid-term CORE EBITDA margin target into the high thirties - moving the opposite way. Asymchem represents a third path: offsetting a slowing small-molecule base with incremental emerging-business revenue, at the cost of structurally lower blended margin. Whether that path works depends on how efficiently peptides and oligonucleotides scale. If emerging-business margin cannot converge from 31% toward 40%, revenue growth will keep translating into profit more weakly than the market expects.

Three things to watch: the 2027 Q1 capacity timeline (management says high-potency lines and peptide synthesis capacity are landing steadily); whether Q4 reaches the upper end of the 19%-22% guidance; and the emerging-business margin curve, which matters more to valuation than revenue growth.